PRODUCT – Talk Bio

MIT’s Boltz-1 AI Model Rivals AlphaFold 3 in Biomolecular Structure Prediction

2 days ago talkbio0Tagged AlphaFold, Aortic Valve Insufficiency, Artificial Intelligence, biomolecular structure prediction, Boltz-1, Drug Discovery, MIT, open-source AI, protein folding

MIT; Boltz-1; AlphaFold 3; AI model; biomolecular structure prediction; drug discovery; protein folding; open-source AI

Ascletis’ Sagimet-Sourced Oral FASN Inhibitor Achieves All Endpoints in Pivotal Acne Study

4 days ago talkbio0Tagged Acne Vulgaris, Ascletis, Biosciences, Chinese study, clinical endpoints, Clinical Trials, Denifanstat, Inhibitor, Lesion, oral FASN, Phase 3, Sagimet

Ascletis; Sagimet Biosciences; denifanstat; oral FASN inhibitor; phase 3 clinical trial; acne vulgaris; clinical endpoints; lesion reduction; Chinese study

Sarepta’s rAAVrh74 Viral Vector Receives FDA Platform Technology Designation for Gene Therapy

4 days ago talkbio0Tagged gene therapy, Infrequent, Muscular Dystrophies, Limb-Girdle, platform technology designation, SRP-9003, United States Food and Drug Administration, Viral Vector

Sarepta Therapeutics; FDA; platform technology designation; rAAVrh74 viral vector; gene therapy; SRP-9003; limb-girdle muscular dystrophy; rare diseases

Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space

3 weeks ago talkbio0Tagged Allo-Glue platform, Drug Discovery, genentech, Malignant Neoplasms, molecular glue, Neoplasms, Orionis Biosciences, Partnership, protein degraders

Genentech; Orionis Biosciences; molecular glue; oncology; drug discovery; cancer; partnership; biotech; protein degraders; Allo-Glue platform

FDA Approves Novavax COVID Vaccine After Delay, Limits Use to Smaller High-Risk Population

3 weeks ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), Health conditions:-:Point in time:^Patient:-, Novavax, Nuvaxovid, protein-based vaccine, restricted population, United States Food and Drug Administration, Vaccines

Novavax; FDA approval; COVID-19 vaccine; Nuvaxovid; restricted population; protein-based vaccine; older adults; underlying health conditions

FDA Delays Decision on Biohaven’s Troriluzole for Rare Disease, Plans Advisory Committee Review

3 weeks ago talkbio0Tagged Advisory Committees, Ataxia, Spinocerebellar, Biohaven, Deferred, disease drug, Extension, Infrequent, Neurodegenerative Disorders, PDUFA, Troriluzole, United States Food and Drug Administration

Biohaven; FDA delay; troriluzole; spinocerebellar ataxia (SCA); rare disease drug; PDUFA extension; advisory committee; neurodegenerative disease

Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus

3 weeks ago talkbio0Tagged Autoimmune Diseases, CAR-T, KYV-101, Kyverna, layoffs, pipeline development, Staff

Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101

OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios

4 weeks ago talkbio0Tagged AI safety, Aortic Valve Insufficiency, Evaluation, HealthBench, healthcare benchmark, language models, medical AI, open-source dataset, OpenAI, Physicians, realistic medical scenarios, rubrics

OpenAI; HealthBench; AI healthcare benchmark; large language models; medical AI evaluation; physician rubrics; realistic medical scenarios; AI safety; open-source dataset

FDA eyes full AI integration by June as Makary touts genAI pilot success

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, DNA Integration, June, Makary, United States Food and Drug Administration

United States Food and Drug Administration, Aortic Valve Insufficiency, DNA Integration, Artificial Intelligence, Makary, June

AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil

1 month ago talkbio0Tagged Ambulatory Care Facilities, Aortic Valve Insufficiency, Artificial Intelligence, Biotech Layoffs, biotechnology layoffs, Drug Discovery, Industry, Insitro, Market, Readiness, restructuring, trends qualifier

Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs